Overview
Post-traumatic hypopituitarism (PTHP) is a significant complication that can arise following sports-related traumatic brain injuries (SR-TBIs), particularly in athletes who have experienced even mild traumatic brain injuries (mTBIs). This condition involves dysfunction of the pituitary gland, leading to deficiencies in one or more pituitary hormones. The clinical implications are profound, affecting growth, metabolism, reproductive function, and stress response. Given the potential for delayed onset and evolving nature of hormone deficiencies, early recognition and ongoing monitoring are crucial. Epidemiological studies suggest that the prevalence of pituitary dysfunction ranges from 15% to 46.6% post-SR-TBIs, highlighting the need for systematic research to better understand its mechanisms, screening protocols, and preventive strategies [PMID:30637622]. Female athletes appear to be a particularly vulnerable group, with studies indicating higher incidences of pituitary dysfunction compared to other populations [PMID:40539611].
Pathophysiology
Traumatic brain injury (TBI), even when mild, can disrupt the delicate structure and function of the pituitary gland, often located in the sellar region near the base of the brain. The mechanical forces exerted during sports-related injuries can lead to direct damage to the gland or compromise its blood supply, resulting in hypopituitarism. This disruption can affect various pituitary hormones, with growth hormone (GH) deficiency being the most frequently reported [PMID:30637622]. The pathophysiology is further complicated by potential secondary effects, such as inflammation and oxidative stress, which may contribute to ongoing pituitary dysfunction over time [PMID:40185676]. Understanding these mechanisms underscores the importance of comprehensive neurological and endocrinological evaluations in athletes post-TBI to identify early signs of pituitary dysfunction.
Epidemiology
The epidemiology of post-traumatic hypopituitarism in athletes remains an evolving field, with significant gaps in large-scale, systematic studies. A notable study involving 308 female athletes with a history of mild traumatic brain injury (mTBI) revealed that 16 women (12.2%) were diagnosed with pituitary dysfunction, encompassing both hypopituitarism and hyperprolactinemia [PMID:40539611]. This finding highlights the vulnerability of female athletes to pituitary dysfunction following sports-related injuries. The reported prevalence of pituitary dysfunction post-SR-TBIs varies widely, ranging from 15% to 46.6%, depending on the study design and inclusion criteria [PMID:30637622]. These variations emphasize the need for standardized screening protocols and larger, more diverse cohorts to establish definitive epidemiological trends. Further research is essential to refine risk stratification and develop targeted prevention strategies.
Clinical Presentation
The clinical presentation of post-traumatic hypopituitarism can be multifaceted and often subtle, making early diagnosis challenging. In female athletes diagnosed with pituitary dysfunction following mTBI, cognitive impairments have been observed, particularly in sustained attention and inhibitory control, as evidenced by significantly higher mean Sustained Attention to Response Task (SART) error scores [PMID:40539611]. Beyond cognitive deficits, athletes may exhibit a spectrum of symptoms related to specific hormone deficiencies. For instance, growth hormone deficiency commonly manifests as fatigue, decreased muscle mass, and impaired recovery from physical exertion [PMID:30637622]. Gonadal axis disturbances can lead to menstrual irregularities in women and decreased libido in both sexes. Central adrenal insufficiency, while less common, is particularly critical due to its acute life-threatening implications, necessitating urgent detection and glucocorticoid replacement [PMID:30637622]. The evolving nature of these deficiencies means that initial evaluations may not capture all deficits, underscoring the necessity for periodic reassessment in affected athletes.
Diagnosis
Diagnosing post-traumatic hypopituitarism requires a multi-faceted approach, integrating neuropsychological assessments with comprehensive endocrinological evaluations. In a study involving 166 female athletes, neuropsychological testing, including the SART, identified cognitive impairments that were further substantiated by pituitary hormone screening blood tests in 88.1% of participants [PMID:40539611]. These initial screenings often reveal abnormalities in growth hormone (GH) levels, which is the most prevalent deficiency observed post-SR-TBIs [PMID:40185676]. For definitive diagnosis, detailed endocrinological testing, such as dynamic hormonal stimulation tests (e.g., insulin tolerance test for GH deficiency), is essential. Central adrenal insufficiency, though less frequent, demands immediate attention due to its potential for acute adrenal insufficiency, requiring prompt cortisol assessment and replacement therapy [PMID:30637622]. Collaboration between neurologists, endocrinologists, and neuropsychologists is crucial for a holistic evaluation and accurate diagnosis.
Differential Diagnosis
Differentiating post-traumatic hypopituitarism from other cognitive and hormonal disturbances following mTBI is critical for appropriate management. Neuropsychological measures, such as the SART, play a pivotal role in distinguishing cognitive impairments specifically linked to pituitary dysfunction from those attributable to other psychological effects or general post-concussive symptoms [PMID:40539611]. Other differential diagnoses include primary psychiatric disorders, medication side effects, and other endocrine disorders (e.g., hypothyroidism). Clinicians must consider the temporal relationship between injury and symptom onset, the pattern of hormone deficiencies, and the presence of other neurological symptoms to rule out alternative causes. Comprehensive baseline assessments before injury, when available, can also aid in distinguishing post-injury changes from pre-existing conditions.
Management
The management of post-traumatic hypopituitarism involves individualized treatment plans tailored to the specific hormone deficiencies identified. Growth hormone (GH) deficiency, the most common, requires careful consideration due to concerns about GH misuse for performance enhancement, which complicates therapeutic decisions [PMID:40185676]. Replacement therapy for GH and gonadal hormones should be individualized, balancing clinical need with regulatory compliance, potentially necessitating therapeutic use exemptions from sports governing bodies [PMID:30637622]. For central adrenal insufficiency, immediate glucocorticoid replacement is imperative to prevent adrenal crisis. Regular monitoring of hormone levels and clinical status is essential to adjust treatments as deficiencies evolve or resolve over time [PMID:30637622]. Psychological support and cognitive rehabilitation may also be beneficial, especially given the observed cognitive impairments in affected athletes [PMID:40539611].
Prognosis & Follow-up
The prognosis for athletes with post-traumatic hypopituitarism varies widely, influenced by the severity and timing of the initial injury, the specific hormones affected, and the timeliness and efficacy of interventions. Some hormone deficiencies may improve spontaneously over time, while others may persist or develop anew, necessitating ongoing surveillance [PMID:30637622]. Regular follow-up evaluations, including periodic hormonal assessments and neuropsychological testing, are crucial to monitor both physical and cognitive recovery. Clinicians should remain vigilant for emerging deficiencies and adjust management strategies accordingly. Long-term follow-up can help in tailoring rehabilitation programs and lifestyle modifications to optimize outcomes and mitigate long-term impacts on athletic performance and overall health.
Special Populations
Female athletes appear to be disproportionately affected by post-traumatic hypopituitarism following sports-related traumatic brain injuries, as evidenced by higher reported incidences of pituitary dysfunction compared to other demographic groups [PMID:40539611]. This vulnerability necessitates tailored monitoring strategies and management approaches that account for gender-specific physiological differences and potential hormonal influences. Tailored screening protocols should be implemented, focusing on early detection and intervention to mitigate cognitive and physical impairments. Given the unique challenges faced by this population, multidisciplinary care involving endocrinologists, neurologists, and sports medicine specialists is particularly important to address the multifaceted needs of female athletes with PTHP. Further research is needed to elucidate gender-specific risk factors and optimal management strategies for this vulnerable group.
References
1 Eggertsdóttir Claessen LÓ, Jónsdóttir MK, Kristjánsdóttir H, Lund SH, Kristensen IU, Sigurjónsdóttir HÁ. Pituitary Dysfunction Following Mild Traumatic Brain Injury in Female Athletes: Neuropsychological and Psychological Findings. NeuroRehabilitation 2025. link 2 Kara CS, Karaca Z. Pituitary dysfunction due to sports injuries. Best practice & research. Clinical endocrinology & metabolism 2025. link 3 Hacioglu A, Kelestimur F, Tanriverdi F. Pituitary dysfunction due to sports-related traumatic brain injury. Pituitary 2019. link
3 papers cited of 4 indexed.